GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » 12-1 Month Momentum %

Invex Therapeutics (ASX:IXC) 12-1 Month Momentum % : 43.08% (As of Jul. 05, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2025-07-05), Invex Therapeutics's 12-1 Month Momentum % is 43.08%.

The industry rank for Invex Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

ASX:IXC's 12-1 Month Momentum % is ranked better than
81.53% of 1424 companies
in the Biotechnology industry
Industry Median: -17.895 vs ASX:IXC: 43.08

Competitive Comparison of Invex Therapeutics's 12-1 Month Momentum %

For the Biotechnology subindustry, Invex Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invex Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's 12-1 Month Momentum % falls into.


;
;

Invex Therapeutics  (ASX:IXC) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invex Therapeutics  (ASX:IXC) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Invex Therapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Invex Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.

Invex Therapeutics Headlines

From GuruFocus

Fisher Asset Management Trims Infosys, Equinor Positions

By Tiziano Frateschi Tiziano Frateschi 02-07-2021

Verger Capital Management LLC Buys iShares Global Energy ETF, iShares Gold Trust

By GuruFocus Research GuruFocus Editor 10-29-2021